Immunotherapy biotech raises $37M from backers like Pfizer, Takeda, BMS
Immunotherapy biotech EvolveImmune Therapeutics raised $37 million in a financing round, backed by big names like Pfizer and its newest investor, Bristol Myers Squibb.
EvolveImmune said it will use the funds to advance its lead T cell engager program, called EV-104, through preclinical studies and into humans in solid tumors. Its first-in-human clinical trials are expected to start in 2024. EV-104 was created using the company’s costimulatory T cell engager platform, dubbed EVOLVE. The company unveiled early data for the candidate in April, where it matched the asset against a CD3 bispecific antibody.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.